MAPT and supranuclear palsy, progressive, 1: Furthermore, there is limited autopsy data investigating tau deposition in PSP as a function of disease duration.23 However, longitudinal in vivo imaging data on PSP clearly indicated changes over time in magnetic resonance imaging measures of atrophy but only minor changes of 18F-flortaucipir binding.29 In summary, large-scale longitudinal studies are needed to investigate the value of 18F-PI-2620 as a progression biomarker in PSP.